Janssen Pharmaceutica Nv

José Manuel Bartolomé -Nebreda

José Ignacio Andrés-Gil

Francisco Javier Fernández-Gadea

Manuel Jesús Alcázar-Vaca

Margaretha Henrica Maria Bakker

Antonius Adrianus Hendrikus Megens

 The invention concerns fused heterocyclic isoxazoline derivatives of Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof, more in particular, tetrahydropyranoisoxazole, hexahydroisoxazolopyridine, tetrahydrothiopyrano isoxazole and hexahydrobenzoisoxazole derivatives fused to a heterocyclic ring system via the 6-membered ring of the bicyclic moiety as well as processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine, in particular for treating depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders including anorexia nervosa and bulimia, wherein the variables are defined as in ClaimThe compounds have surprisingly been shown to have selective serotonine (5-HT) reuptake inhibitor activity as well as &#x3b1;-adrenoceptor antagonist activity, compounds according to the invention are also suitable for treatment and/or prophylaxis in diseases where either one of the activities alone or the combination of said activities may be of therapeutic use.

Growing community of inventors

Toledo, Spain

José Manuel Bartolomé -Nebreda